Loading...
Adding immune checkpoint inhibitors to first-line chemotherapy for patients with metastatic gastric cancer improves response, progression-free survival (PFS) and overall survival (OS). The benefit is limited to patients testing positive for a combined score for PDL-1.
Investigators now report the results of a multinational, industry-sponsored, placebo-controlled randomized trial comparing investigators' choice of first-line chemotherapy (capecitabine/oxaliplatin or infusional 5-FU/cisplatin) with versus without the addition of the anti–PD-1 agent tislelizumab (200 mg every 3 weeks). Of the 997 patients enrolled, 75% were treated in Asia, 38% had liver metastases, 44% had peritoneal metastases, 80% had gastric primary tumors, and 4% had micro…